Aurora Spine has announced the first US surgical usage of its AmnioPUR liquid allograft product in a lumbar spinal procedure. Introduced at both EuroSpine and the North American Spine Society (NASS) annual meeting, AmnioPUR has now been launched globally.
According to a press release, AmnioPUR is a multipurpose, chorion-free, cryopreserved allograft that is derived from the amniotic membrane. The press release adds that allgoraft provides an anti-microbial environment with anti-inflammatory characteristics and anti-adhesion/anti-fibrotic capabilities and provides a structural matrix for use in filling bone voids and soft tissue.
“The launch of AmnioPUR is a major milestone for Aurora Spine, as we now offer surgeons a comprehensive liquid allograft solution from a provider they trust,” said Trent J Northcutt, president and chief executive officer of Aurora Spine. “Surgeons know Aurora provides modern technologies for today’s patients ailing from spinal complications. Aurora is committed to the development, distribution and licensing arrangements of advanced biologics and tissue allografts, which make up one of the fastest growing segments in the global spine market.”
